CSPC PHARMA (01093.HK): SYS6062 ADC gets China clinical trial nod
On 15 October 2026, CSPC PHARMA (01093.HK) said SYS6062, a monoclonal antibody-drug conjugate, won China clinical trial approval for advanced solid tumours.
Key Highlights:
- The product binds specific receptors on tumour cell surfaces, enters cells through endocytosis and releases toxins to kill tumour cells.
- It was filed as a Class 1 therapeutic biological product, and the approved indication is advanced solid tumours.
NewTimeSpace News: On 15 October 2026, CSPC Pharmaceutical Group Limited (01093.HK) announced that SYS6062, developed by the Group, has been approved by the National Medical Products Administration of the PRC for clinical trials in China. The product is a monoclonal antibody-drug conjugate that binds to specific receptors on tumour cell surfaces, enters cells through endocytosis and releases toxins to kill tumour cells. It was filed as a Class 1 therapeutic biological product, with the approved indication being advanced solid tumours. Preclinical studies showed anti-tumour activity against multiple cancers, with good efficacy expected in subsequent clinical trials.
Tags：
- CSPC PHARMA (01093.HK): SYS6088 trispecific antibody gets CT nod
- CSPC PHARMA (01093.HK): Phase I Data for SYS6002 in Advanced Cervical Cancer; Confirmed ORR Up to 35.9%
- CSPC PHARMA (01093.HK): 8 trials to feature at ESMO 2026, two as LBAs
- CSPC PHARMA (01093.HK): Efmedaglutide Alfa Phase III Data at EASD 2026
- CSPC PHARMA (01093.HK): JMT206 Phase Ib Obesity Trial Starts in China
